Ex Vivo Pilot Study of the Impact of Nasal Breathing During the Administration of Inhaled Corticosteroids by Inhalation Chamber in Asthmatic Children Ages Between 1 and 4-year-old (MASQUE)

P

Public Assistance-Hospitals of Marseille (AP-HM)

Status

Unknown

Conditions

Asthma in Children

Treatments

Other: Corticosteroids inhalation

Study type

Interventional

Funder types

Other

Identifiers

NCT03364959
2016-47
2016-A01839-42 (Other Identifier)

Details and patient eligibility

About

The main purpose of this open randomized, ex-vivo comparative study, is to assess and to compare the inhalable dose of inhaled corticosteroid collected through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber

Full description

The use of a face mask is recommended for inhaled treatments delivered from a pressurized metered-dose inhaler and a spacer device in infants and young children with respiratory disorders such as asthma. The nose effectively filters the air particles and it may reduce the amount of inhaled drug. Thus it is reported that the drug deposited in the lung dose is halved in older children inhaling through the nose with respect to those inhaling through the mouth. In very young children the efficiency of nasal filtration is unknown for inhaled treatment. In infants, an in-vitro study suggests that nasal breathing allows a similar or more important drug delivery than mouth breathing, contrary to what is observed in the oldest and adults. So it seems of great import to characterize the drug delivery in this age group comparing the nasal with the mouth breathing. The main purpose of this open randomized, ex-vivo comparative study, is to assess and to compare the inhalable dose of inhaled corticosteroid collected through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber. 60 children, aged between 1 and 4 years old, with a medically diagnosed asthma will be recruited. Each child will inhale four puffs of both Fluticasone 125 µg/puff and Beclometasone dipropionate 100 µg/puff administered by a single observer in a standardized and randomized way. No drug will be inhaled by the children. The drugs collected on the filters between the holding chamber and patient will be analysed by high performance liquid chromatography HPLC). Filter doses will be expressed in percentage of the total dose filtered. The analysis will cover the difference between oral dose and nasal dose compared to zero. Student's test will be performed with p < 0.05.

Enrollment

60 estimated patients

Sex

All

Ages

1 to 4 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Aged from 1 to 4 years old
  • Male or female
  • With medically diagnosed asthma
  • Patients who are used to use an inhalation chamber with a face mask
  • Patients who have not had asthmatic decompensation for at least 1 month.
  • Patients' parents having given their written consent
  • With normal clinical respiratory examination on the day of the test.

Exclusion criteria

  • Patients whose parents are unable to understand the purpose and conditions of the study
  • Patients whose parents are unable to give their consent
  • Patients participating in another clinical trial or exclusion period from a previous clinical trial
  • Patients presenting with a nasopharyngeal infection in the previous month
  • Child with nasal obstruction, nocturnal snoring, adenoid facies or facial malformation
  • Patient presenting with an asthmatic decompensation episode in the previous month

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

60 participants in 2 patient groups

Flixotide
Experimental group
Description:
Patients inhale first Flixotide and then Qvar
Treatment:
Other: Corticosteroids inhalation
Qvar
Experimental group
Description:
Patients inhale first Qvar and then Flixotide
Treatment:
Other: Corticosteroids inhalation

Trial contacts and locations

0

Loading...

Central trial contact

Camille DELANNOY, Manager; Jean-Christophe DUBUS, PD-PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems